» Articles » PMID: 16761297

The Near Universal Presence of Autism Spectrum Disorders in Children with Smith-Lemli-Opitz Syndrome

Overview
Specialty Genetics
Date 2006 Jun 9
PMID 16761297
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive condition caused by a defect in cholesterol synthesis. Affected children often have malformations and mental retardation. Autistic behaviors also are evident. The purpose of the present study was to determine the prevalence of autism spectrum disorders (ASDs) in children with SLOS. Fourteen children, 3-16 years old, were evaluated using three different methods to document autistic symptoms: (a) parent interview, (b) direct observation, and (c) a behavior checklist. Blood sterols were also measured at regular intervals. Each subject was determined to have Autistic Disorder, Pervasive Developmental Disorder, not otherwise specified (PDD NOS), or no diagnosis on the autism spectrum, based on DSM-IV criteria. Correlations among variables were calculated, and blood sterol levels were compared between diagnostic groups. Approximately three-fourths of the children with SLOS (71-86% depending on the evaluation method) had an ASD, about 50% diagnosed with Autistic Disorder and the rest with PDD NOS. The children's baseline cholesterol, 7-dehydrocholesterol (7-DHC), and 8-dehydrocholesterol (8-DHC) levels, and cholesterol levels following supplementation did not correlate with the presence or severity of autistic symptoms. These results suggest that most children with SLOS have some variant of autism. SLOS appears to have the most consistent relationship with autism of any single gene disorder. Therefore, a link between cholesterol metabolism and autism is suggested. With further study, these findings, together with knowledge of the genetic and biochemical defects in SLOS, will likely provide valuable insights into the causes of autism in general.

Citing Articles

Gangliosides and Cholesterol: Dual Regulators of Neuronal Membrane Framework in Autism Spectrum Disorder.

Puljko B, Stracak M, Kalanj-Bognar S, Todoric Laidlaw I, Mlinac-Jerkovic K Int J Mol Sci. 2025; 26(3).

PMID: 39941090 PMC: 11818915. DOI: 10.3390/ijms26031322.


Elevated cerebrospinal fluid glial fibrillary acidic protein levels in Smith-Lemli-Opitz syndrome.

Luke R, Cawley N, Rahhal S, Selvaraman A, Thurm A, Wassif C Mol Genet Metab. 2024; 143(1-2):108570.

PMID: 39244853 PMC: 11473222. DOI: 10.1016/j.ymgme.2024.108570.


Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS).

Korade Z, Anderson A, Sharma K, Tallman K, Kim H, Porter N Mol Psychiatry. 2024; 29(12):3942-3949.

PMID: 38844533 DOI: 10.1038/s41380-024-02622-5.


Temporal gene expression changes and affected pathways in neurodevelopment of a mouse model of Smith-Lemli-Opitz syndrome.

Li A, Tomita H, Xu L bioRxiv. 2023; .

PMID: 38045361 PMC: 10690207. DOI: 10.1101/2023.11.21.568116.


Biochemical, Genetic and Clinical Diagnostic Approaches to Autism-Associated Inherited Metabolic Disorders.

Senarathne U, Indika N, Jezela-Stanek A, Ciara E, Frye R, Chen C Genes (Basel). 2023; 14(4).

PMID: 37107561 PMC: 10138025. DOI: 10.3390/genes14040803.